A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers

Trial Profile

A Randomized , Open-label, Multicenter, Phase II Study to Compare the Efficacy of S-1 and S-1 Plus Leucovorin as Second Line Treatment on Gemcitabine-refractory Patients With Inoperable or Advanced Pancreatic Cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Folinic acid
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms APC-S1
  • Most Recent Events

    • 30 May 2014 Primary endpoint 'Progression-free-survival' has not been met.
    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top